«We know people
with myeloproliferative disorders, such as essential thrombocythemia, produce too many megakaryocytes and platelets,» he said.
We investigated the role of the cytoplasmic tyrosine kinase JAK2 in patients
with a myeloproliferative disorder.
Interpretation: A single acquired mutation of JAK2 was noted in more than half of patients
with a myeloproliferative disorder.
Not exact matches
The Johns Hopkins Center for the Chronic
Myeloproliferative Disorders coordinates the care of patients
with PV and other related
disorders and conducts research in these areas.
Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the
myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia
with myelofibrosis.
Myeloproliferative neoplasms (MPNs) are a group of related clonal hemopoietic stem cell
disorders associated
with hyperproliferation of myeloid cells.